Interaction of lytic phage T1245 with antibiotics for enhancement of antibacterial and anti-biofilm efficacy against multidrug-resistant Acinetobacter baumannii

References

• Aghapour Z, Gholizadeh P, Ganbarov K, Bialvaei AZ, Mahmood SS, Tanomand A, Yousefi M, Asgharzadeh M, Yousefi B, Kafil HS. 2019. Molecular mechanisms related to colistin resistance in Enterobacteriaceae. Infect Drug Resist. 12:965–975. doi:10.2147/IDR.S199844
   PubMed Web of Science ®Google Scholar
• Al-Shamiri MM, Zhang S, Mi P, Liu Y, Xun M, Yang E, Ai L, Han L, Chen Y. 2021. Phenotypic and genotypic characteristics of Acinetobacter baumannii enrolled in the relationship among antibiotic resistance, biofilm formation and motility. Microb Pathog. 155:104922.
   PubMed Web of Science ®Google Scholar
• Asadian M, Azimi L, Alinejad F, Ostadi Y, Lari AR. 2019. Molecular characterization of Acinetobacter baumannii isolated from ventilator-associated pneumonia and burn wound colonization by random amplified polymorphic DNA polymerase chain reaction and the relationship between antibiotic susceptibility and biofilm production. Adv Biomed Res. 8:58. doi:10.4103/abr.abr_256_18
   PubMedGoogle Scholar
• Blanco N, Harris AD, Rock C, Johnson JK, Pineles L, Bonomo RA, Srinivasan A, Pettigrew MM, Thom KA. 2018. Risk factors and outcomes associated with multidrug-resistant Acinetobacter baumannii upon intensive care unit admission. Antimicrob Agents Chemother. 62:e01631–01617. doi:10.1128/AAC.01631-17
   PubMedGoogle Scholar
• Blasco L, Ambroa A, Lopez M, Fernandez-Garcia L, Bleriot I, Trastoy R, Ramos-Vivas J, Coenye T, Fernandez-Cuenca F, Vila J, et al. 2019. Combined use of the Ab105-2φΔCI lytic mutant phage and different antibiotics in clinical isolates of multi-resistant Acinetobacter baumannii. Microorganisms. 7:556. doi:10.3390/microorganisms7110556
   PubMed Web of Science ®Google Scholar
• Boinett CJ, Cain AK, Hawkey J, Do Hoang NT, Khanh NNT, Thanh DP, Dordel J, Campbell JI, Lan NPH, Mayho M. 2019. Clinical and laboratory-induced colistin-resistance mechanisms in Acinetobacter baumannii. Microb Genom. 5:e000246.
   PubMed Web of Science ®Google Scholar
• Chiang SR, Jung F, Tang HJ, Chen CH, Chen CC, Chou HY, Chuang YC. 2018. Desiccation and ethanol resistances of multidrug resistant Acinetobacter baumannii embedded in biofilm: the favorable antiseptic efficacy of combination chlorhexidine gluconate and ethanol. J Microbiol Immunol Infect. 51:770–777. doi:10.1016/j.jmii.2017.02.003
   PubMedGoogle Scholar
• Chung ES, Ko KS. 2019. Eradication of persister cells of Acinetobacter baumannii through combination of colistin and amikacin antibiotics. J Antimicrob Chemother. 74:1277–1283. doi:10.1093/jac/dkz034
   PubMed Web of Science ®Google Scholar
• Clinical and Laboratory Standards Institute (CLSI). 2020. Performance standards for antimicrobial susceptibility testing. 30th ed. CLSI Document M100. Wayne (PA): CLSI.
   Google Scholar
• Colquhoun JM, Rather PN. 2020. Insights into mechanisms of biofilm formation in Acinetobacter baumannii and implications for uropathogenesis. Front Cell Inf Microbiol. 10:253.
   PubMed Web of Science ®Google Scholar
• Comeau AM, Tétart F, Trojet SN, Prere M-F, Krisch H. 2007. Phage-antibiotic synergy (PAS): β lactam and quinolone antibiotics stimulate virulent phage growth. PLoS One. 2:e799. doi:10.1371/journal.pone.0000799
   PubMed Web of Science ®Google Scholar
• Eliopoulos GM, Eliopoulos CT. 1988. Antibiotic combinations: should they be tested? Clin Microbiol Rev. 1:139–156. doi:10.1128/CMR.1.2.139
   PubMedGoogle Scholar
• Grygorcewicz B, Roszak M, Golec P, Śleboda-Taront D, Łubowska N, Górska M, Jursa-Kulesza J, Rakoczy R, Wojciuk B, Dołęgowska B. 2020. Antibiotics act with vb_abap_agc01 phage against Acinetobacter baumannii in human heat-inactivated plasma blood and Galleria mellonella models. IJMS. 21:4390. doi:10.3390/ijms21124390
   Google Scholar
• Grygorcewicz B, Wojciuk B, Roszak M, Łubowska N, Błażejczak P, Jursa-Kulesza J, Rakoczy R, Masiuk H, Dołęgowska B. 2021. Environmental phage-based cocktail and antibiotic combination effects on Acinetobacter baumannii biofilm in a human urine model. Microb Drug Resist. 27:25–35. doi:10.1089/mdr.2020.0083
   PubMed Web of Science ®Google Scholar
• Gu LC, Green SI, Min L, Clark JR, Salazar KC, Terwilliger AL, Kaplan HB, Trautner BW, Ramig RF, Maresso AW. 2020. Phage-antibiotic synergy is driven by a unique combination of antibacterial mechanism of action and stoichiometry. MBio. 11:e01462–01420.
   PubMed Web of Science ®Google Scholar
• Gupta A, Makabenta JMV, Schlüter F, Landis RF, Das R, Cuppels M, Rotello VM. 2020. Functionalized polymers enhance permeability of antibiotics in gram‐negative MDR bacteria and biofilms for synergistic antimicrobial therapy. Adv Therap. 3:2000005. doi:10.1002/adtp.202000005
   Google Scholar
• Harding CM, Hennon SW, Feldman MF. 2018. Uncovering the mechanisms of Acinetobacter baumannii virulence. Nat Rev Microbiol. 16:91–102. doi:10.1038/nrmicro.2017.148
   PubMed Web of Science ®Google Scholar
• Hayes MV, Orr DC. 1983. Mode of action of ceftazidime: affinity for the penicillin-binding proteins of Escherichia coli K12, Pseudomonas aeruginosa and Staphylococcus aureus. J Antimicrob Chemother. 12:119–126. doi:10.1093/jac/12.2.119
   PubMed Web of Science ®Google Scholar
• Hua Y, Luo T, Yang Y, Dong D, Wang R, Wang Y, Xu M, Guo X, Hu F, He P. 2018. Phage therapy as a promising new treatment for lung infection caused by carbapenem-resistant Acinetobacter baumannii in mice. Front Microbiol. 8:2659.
   PubMed Web of Science ®Google Scholar
• Jansen M, Wahida A, Latz S, Krüttgen A, Häfner H, Buhl EM, Ritter K, Horz H-P. 2018. Enhanced antibacterial effect of the novel T4-like bacteriophage KARL-1 in combination with antibiotics against multi-drug resistant Acinetobacter baumannii. Sci Rep. 8:14140. doi:10.1038/s41598-018-32344-y
   PubMed Web of Science ®Google Scholar
• Jones TE, Selby PR, Mellor CS, Cheam DB. 2019. Ceftazidime stability and pyridine toxicity during continuous iv infusion. Am J of Health-Syst Pharm. 76:200–205. doi:10.1093/ajhp/zxy035
   PubMed Web of Science ®Google Scholar
• Kim M, Jo Y, Hwang YJ, Hong HW, Hong SS, Park K, Myung H. 2018. Phage-antibiotic synergy via delayed lysis. Appl Environ Microbiol. 84:e02085–02018. doi:10.1128/AEM.02085-18
   PubMed Web of Science ®Google Scholar
• Kim M, Park J, Park W. 2021. Genomic and phenotypic analyses of multidrug-resistant Acinetobacter baumannii NCCP 16007 isolated from a patient with a urinary tract infection. Virulence. 12:150–164. doi:10.1080/21505594.2020.1867421
   PubMed Web of Science ®Google Scholar
• Kropinski AM, Mazzocco A, Waddell TE, Lingohr E, Johnson RP. 2009. Enumeration of bacteriophages by double agar overlay plaque assay. In Clokie MRJ, Kropinski, AM, editors. Methods in molecular biology. Vol. 501. New York (NY): Humana Press; p. 69–76.
   Google Scholar
• Kwiatek M, Parasion S, Rutyna P, Mizak L, Gryko R, Niemcewicz M, Olender A, Łobocka M. 2017. Isolation of bacteriophages and their application to control Pseudomonas aeruginosa in planktonic and biofilm models. Res Microbiol. 168:194–207. doi:10.1016/j.resmic.2016.10.009
   PubMed Web of Science ®Google Scholar
• Latka A, Maciejewska B, Majkowska-Skrobek G, Briers Y, Drulis-Kawa Z. 2017. Bacteriophage-encoded virion-associated enzymes to overcome the carbohydrate barriers during the infection process. Appl Microbiol Biotechnol. 101:3103–3119. doi:10.1007/s00253-017-8224-6
   PubMed Web of Science ®Google Scholar
• Li X, Song Y, Wang L, Kang G, Wang P, Yin H, Huang H. 2021. A potential combination therapy of berberine hydrochloride with antibiotics against multidrug-resistant Acinetobacter baumannii. Front Cell Infect Microbiol. 11:660431.
   PubMed Web of Science ®Google Scholar
• Lin Y, Chang RYK, Britton WJ, Morales S, Kutter E, Chan H-K. 2018. Synergy of nebulized phage PEV20 and ciprofloxacin combination against Pseudomonas aeruginosa. Int J Pharm. 551:158–165. doi:10.1016/j.ijpharm.2018.09.024
   PubMedGoogle Scholar
• Liu X, Wu X, Tang J, Zhang L, Jia X. 2020. Trends and development in the antibiotic-resistance of Acinetobacter baumannii: a scientometric research study (1991–2019). Infect Drug Resist. 13:3195–3208. doi:10.2147/IDR.S264391
   PubMed Web of Science ®Google Scholar
• Loraine J, Heinz E, Soontarach R, Blackwell GA, Stabler RA, Voravuthikunchai SP, Srimanote P, Kiratisin P, Thomson NR, Taylor PW. 2020. Genomic and phenotypic analyses of Acinetobacter baumannii isolates from three tertiary care hospitals in Thailand. Front Microbiol. 11:548. doi:10.3389/fmicb.2020.00548
   PubMed Web of Science ®Google Scholar
• Naidu V, Shah B, Kamath KS, Chien A, Nagy S, Pokhrel A, Molloy M, Hassan KA, Paulsen IT. 2021. Identification of a novel ciprofloxacin tolerance gene, aciT, which contributes to filamentation in Acinetobacter baumannii. Antimicrob Agent Chemother. 65:e01400–01420.
   PubMed Web of Science ®Google Scholar
• Nir-Paz R, Gelman D, Khouri A, Sisson BM, Fackler J, Alkalay-Oren S, Khalifa L, Rimon A, Yerushalmy O, Bader R, et al. 2019. Successful treatment of antibiotic-resistant, poly-microbial bone infection with bacteriophages and antibiotics combination. Clin Infect Dis. 69:2015–2018. doi:10.1093/cid/ciz222
   PubMed Web of Science ®Google Scholar
• Nwabor OF, Terbtothakun P, Voravuthikunchai SP, Chusri S. 2021. Evaluation of the synergistic antibacterial effects of fosfomycin in combination with selected antibiotics against carbapenem–resistant Acinetobacter baumannii. Pharmaceuticals. 14:185. doi:10.3390/ph14030185
   Web of Science ®Google Scholar
• Özkul C, Hazırolan G. 2021. Oxacillinase gene distribution, antibiotic resistance, and their correlation with biofilm formation in Acinetobacter baumannii bloodstream isolates. Microb Drug Resist. 27:637–646. doi:10.1089/mdr.2020.0130
   PubMed Web of Science ®Google Scholar
• Pormohammad A, Mehdinejadiani K, Gholizadeh P, Nasiri MJ, Mohtavinejad N, Dadashi M, Karimaei S, Safari H, Azimi T. 2020. Global prevalence of colistin resistance in clinical isolates of Acinetobacter baumannii: a systematic review and meta-analysis. Microb Pathog. 139:103887. doi:10.1016/j.micpath.2019.103887
   PubMed Web of Science ®Google Scholar
• Reena AAA, Subramaniyan A, Kanungo R. 2017. Biofilm formation as a virulence factor of Acinetobacter baumannii: an emerging pathogen in critical care units. J Curr Res Sci Med. 3:74–78. doi:10.4103/jcrsm.jcrsm_66_17
   Google Scholar
• Rizk SS, Elwakil WH, Attia AS. 2021. Antibiotic-resistant Acinetobacter baumannii in low-income countries (2000–2020): twenty-one years and still below the radar, is it not there or can they not afford to look for It? Antibiotics. 10:764. doi:10.3390/antibiotics10070764
   Google Scholar
• Russo A, Bassetti M, Ceccarelli G, Carannante N, Losito AR, Bartoletti M, Corcione S, Granata G, Santoro A, Giacobbe DR. 2019. Bloodstream infections caused by carbapenem-resistant Acinetobacter baumannii: clinical features, therapy and outcome from a multicenter study. J Infect. 79:130–138. doi:10.1016/j.jinf.2019.05.017
   PubMed Web of Science ®Google Scholar
• Ryan EM, Alkawareek MY, Donnelly RF, Gilmore BF. 2012. Synergistic phage-antibiotic combinations for the control of Escherichia coli biofilms in vitro. FEMS Immunol Med Microbiol. 65:395–398. doi:10.1111/j.1574-695X.2012.00977.x
   PubMedGoogle Scholar
• Santimaleeworagun W, Thunyaharn S, Juntanawiwat P, Thongnoy N, Harindhanavudhi S, Nakeesathit S, Teschumroon S. 2020. The prevalence of colistin-resistant Gram-negative bacteria isolated from hospitalized patients with bacteremia. J Appl Pharm Sci. 10:056–059.
   Google Scholar
• Shenkutie AM, Yao MZ, Siu GK-h, Wong BKC, Leung PH-m 2020. Biofilm-induced antibiotic resistance in clinical Acinetobacter baumannii isolates. Antibiotics. 9:817. doi:10.3390/antibiotics9110817
   Google Scholar
• Siringan P, Connerton PL, Payne RJ, Connerton IF. 2011. Bacteriophage-mediated dispersal of Campylobacter jejuni biofilms. Appl Environ Microbiol. 77:3320–3326. doi:10.1128/AEM.02704-10
   PubMed Web of Science ®Google Scholar
• Soontarach R, Srimanote P, Enright MC, Blundell-Hunter G, Dorman MJ, Thomson NR, Taylor PW, Voravuthikunchai SP. 2022. Isolation and characterisation of bacteriophage selective for key Acinetobacter baumannii capsule chemotypes. Pharmaceuticals. 15:443. doi:10.3390/ph15040443
   Web of Science ®Google Scholar
• Teerawattanapong N, Panich P, Kulpokin D, Ranong SN, Kongpakwattana K, Saksinanon A, Goh B-H, Lee L-H, Apisarnthanarak A, Chaiyakunapruk N. 2018. A systematic review of the burden of multidrug-resistant healthcare-associated infections among intensive care unit patients in Southeast Asia: the rise of multidrug-resistant Acinetobacter baumannii. Infect Control Hosp Epidemiol. 39:525–533. doi:10.1017/ice.2018.58
   PubMed Web of Science ®Google Scholar
• Tipton KA, Chin C-Y, Farokhyfar M, Weiss DS, Rather PN. 2018. Role of capsule in resistance to disinfectants, host antimicrobials, and desiccation in Acinetobacter baumannii. Antimicrob Agents Chemother. 62:e01188–01118. doi:10.1128/AAC.01188-18
   PubMed Web of Science ®Google Scholar
• Wang JL, Kuo CF, Yeh CM, Chen JR, Cheng MF, Hung CH. 2018. Efficacy of φkm18p phage therapy in a murine model of extensively drug-resistant Acinetobacter baumannii infection. Infect Drug Resist. 11:2301–2310. doi:10.2147/IDR.S179701
   PubMed Web of Science ®Google Scholar
• Wang X, Loh B, Gordillo Altamirano F, Yu Y, Hua X, Leptihn S. 2021. Colistin-phage combinations decrease antibiotic resistance in Acinetobacter baumannii via changes in envelope architecture. Emerg Microbes Infect. 10:2205–2219. doi:10.1080/22221751.2021.2002671
   PubMed Web of Science ®Google Scholar
• Wintachai P, Phaonakrop N, Roytrakul S, Naknaen A, Pomwised R, Voravuthikunchai SP, Surachat K, Smith DR. 2022. Enhanced antibacterial effect of a novel Friunavirus phage vWU2001 in combination with colistin against carbapenem-resistant Acinetobacter baumannii. Sci Rep. 12:2633. doi:10.1038/s41598-022-06582-0
   PubMed Web of Science ®Google Scholar
• Xiao J, Zhang C, Ye S. 2019. Acinetobacter baumannii meningitis in children: a case series and literature review. Infection. 47:643–649. doi:10.1007/s15010-018-1234-1
   PubMed Web of Science ®Google Scholar
• Xu Q, Chen T, Yan B, Zhang L, Pi B, Yang Y, Zhang L, Zhou Z, Ji S, Leptihn S, et al. 2019. Dual role of gnaA in antibiotic resistance and virulence in Acinetobacter baumannii. Antimicrob Agents Chemother. 63:e00694–00619. doi:10.1128/AAC.00694-19
   PubMed Web of Science ®Google Scholar
• Yang CH, Su PW, Moi SH, Chuang L-Y. 2019. Biofilm formation in Acinetobacter Baumannii: genotype-phenotype correlation. Molecules. 24:1849. doi:10.3390/molecules24101849
   PubMed Web of Science ®Google Scholar
• Yin S, Huang G, Zhang Y, Jiang B, Yang Z, Dong Z, You B, Yuan Z, Hu F, Zhao Y, et al. 2017. Phage Abp1 rescues human cells and mice from infection by pan-drug resistant Acinetobacter baumannii. Cell Physiol Biochem. 44:2337–2345. doi:10.1159/000486117
   PubMedGoogle Scholar
• Zaidan N, Hornak JP, Reynoso D. 2021. Extensively drug-resistant Acinetobacter baumannii nosocomial pneumonia successfully treated with a novel antibiotic combination. Antimicrob Agents Chemother. 65:e00924-00921. doi:10.1128/AAC.00924-21
   Web of Science ®Google Scholar
• Zeighami H, Valadkhani F, Shapouri R, Samadi E, Haghi F. 2019. Virulence characteristics of multidrug resistant biofilm forming Acinetobacter baumannii isolated from intensive care unit patients. BMC Infect Dis. 19:629. doi:10.1186/s12879-019-4272-0
   PubMed Web of Science ®Google Scholar